«Особенности хирургического этапа лечения рака молочной железы после неоадъювантной системной терапии» (стр. 16 )

47.  Brent B., Bostwick J. (1977) Nipple-areola reconstruction with auricular tissues. Plast Reconstr Surg., 60: 353–361.

48.  Blondeel P. N. (1999) The sensate free superior gluteal artery perforator (S-GAP) flap: a valuable alternative in autologous breast reconstruction. Br J Plast Surg., 52: 185–193.

49.  Bostwick J., III, Schlefan M. (1980) The latissimus dorsi musculocutaneous flap: a one-stage breast reconstruction. Clin Plast Surg., 7: 71–78.

50.  Becker H. (1984) Breast reconstruction using an inflatable breast implant with detachable reservoir. Plast Reconstr Surg., 73: 678–683.

51.  Birnbaum L., Olsen J. A. (1978) Breast reconstruction following radical mastectomy, using custom designed implants. Plast Reconstr Surg., 61: 355–363.

52.  Bayraktar S, Gonzalez-Angulo AM, Lei X, et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline - and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 2012 May 1;118 vol. 9.-pp 2385–93.

53.  Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, openlabel, multicentre, phase 3 trial. Lancet 2012 Feb vol. 18;379(9816) . - pp 633–40.

54.  Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005 Jun 1;23vol. 16.-pp3676–85.

55.  Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006 May 1; 24 vol. 13.-2019–27.

56.  Berruti A, Generali D, Kaufmann M, et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr 2011;2011 vol. 43.-pp147–51.

57.  Cronin K. A., Ravdin P. M., Edwards B. K. (2009) Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat., 117: 223–224.

58.  Canfell K., Banks E., Moa A. M., Beral V. (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust., 188: 641–644.

59.  Clough K. B. et al. (2003) Oncoplastic techniques allow for extensive resections for breast-conserving therapy of breast carcinomas. Ann Surg, 237: 26–34.

60.  Clough K. B., Kaufman G. J., Nos C. et al. (2010) Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. Ann Surg Oncol.,179(5): 1375–91.

61.  Cronin T. D., Gerow F. J. (1963) Augmentation mammaplasty: a new “natural feel” prosthesis. Amsterdam: In: Transactions of the Third International Congress of Plastic and Reconstructive Surgery; Excerpta Medica.

62.  Clough K. B., O’Donoghue J. M., Fitoussi A. D. et al. (2001) Prospective evaluation of late cosmetic results following breast reconstruction: II. Tram flap reconstruction. Plast Reconstr Surg., 107: 1710–1716.

63.  Cure H, Amat S, Penault-Llorca F, et al. Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer Res Treat 2002 vol.76-pp.37–45.

64.  Colleoni M, Bagnardi V, Rotmensz N, et al. A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Ann Oncol 2009 vol. 20-pp. 1178–84.

65.  Colleoni M, Minchella I, Mazzarol G, et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000 vol.11-pp 1057–9.

66.  Czerny V. (1895) Plastic replacement of the breast with a lipoma. Chir Kong Verhandl., 2: 216.

67.  Cortazar PZL, Untch M, Mehta K, et al. Meta-analysis results from the Collaborative trials in neoadjuvant breast cancer (CTNeoBC). [103s abst]. Cancer Res 2012;72 vol. 24.-pp:S1–S11.

68.  Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 2011;103:1656–64.

69.  Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005 vol.11-pp.951s–8s.

70.  De Los Santos J, Bernreuter W, Keene K, et al. Accuracy of breast magnetic resonance imaging in predicting pathologic response inCancer 2011 Oct;11 vol. 5.-pp 312–9.

71.  Earl AV HM, Hiller L, Fenwick N, et al. for NeotAnGo Investigators. Neo-tAnGo: a neoadjuvant randomised phase III trial of epirubicin/cyclophosphamide (EC) and paclitaxel (T) gemcitabine (G) in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint e pathological complete response (pCR). J Clin Oncol 2009;27 vol. 15.-pp 522.

72.  Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TrialeCALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012 Sep 10;30 vol. 26.-pp 3242–9.

73.  Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403–10.

74.  Ellis MJ, Miller WR, Tao Y, et al. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. Breast Cancer Res Treat 2008 vol.116-pp.371–8.

75.  Elliott L. F., Hartrampf C. R. Jr. (1990) Breast reconstruction: progress in the past decade. World J Surg., 14: 763–775.

76.  Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB Study. J Clin Oncol 2012 Jun 1;30 vol. 16.-pp 1989–95.

77.  Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006 vol. 24-pp.1037–44.

78.  Guarneri V, Piacentini F, Ficarra G, et al. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 2009 vol.20-pp.1193–8.

79.  Grotting J. C., Urist M. M., Maddos W. A., Vasconez L. O. (1989) Conventional TRAM flap versus free microsurgical TRAM flap for immediate breast reconstruction. Plast Reconstr Surg., 83: 828–841.

80.  Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012 Jan; vol. 13(1).pp 25–32.

81.  Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH Trial): a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010 Jan vol. 30;375.-pp 377–84.

82.  Gilles H. D, Millard D. R. (1957) Principles and Art of Plastic Surgery. Boston: Little Brown & Company.

83.  Holmström H. (1979) The free abdominoplasty flap and its use in breast reconstruction. Scand J Plast Reconstr Surg., 13: 423–427.

84.  Hartrampf C. R. Jr. (1987) Breast reconstruction with a transverse abdominal island flap. A retrospective evaluation of 335 patients. Perspect Plast Surg., 1: 123.

85.  Hartrampf C. R., Scheflan M., Black P. W. (1982) Breast reconstruction with a transverse abdominal island flap. Plast Reconstr Surgery, 69: 216–225.

86.  Hokin J. A., Silfverskiold K. L. (1987) Breast reconstruction without an implant: Results and complications using an extended latissimus dorsi flap. Plast Reconstr Surg., 79: 58–66.

87.  Höhler H. (1977) Carcinoma of the breast. Reconstructive surgery. Langenbecks Arch Chir., 345: 78–86.

88.  Hayward J. (1983) In: Harris J. R., Hellman S., Silen W., editor. Conservative Management of Breast Cancer. Philadelphia: Lippincott. The Guy’s Hospital trials on breast conservation.

89.  Holmes YMN FA, Espina VA, Liotta LA, et al. Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. J Clin Oncol 2011; vol.29(Suppl.):29. [abstr 506].

90.  Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012 Dec;48 vol. 18.-pp 3342–54.Heys SDHA, Sarkar TK, Ogston KN, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial Aberdeen Breast ppl. X. Clin Breast Cancer 2002 Oct;3(S2) pp:69–74.

91.  http://clinicaltrials. gov/show/NCT01772472.

92.  Jones RL, Salter J, A’Hern R, et al. Relationship between oestrogen receptor status and proliferation in predicting response and longterm outcome to neoadjuvant chemotherapy for breast cancer. BreastCancer Res Treat 2010. – vol.119- pp.315–23.

93.  Jones RL, Smith IE. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol 2006 vol.7-pp 869–74.